synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
As of 2005, India was the only country producing licit opium (opium gum) for both domestic use and export. Licit opium was produced also in Democratic People's Republic of Korea for domestic use, and in Japan for maintenance of the pertinent technology (small quantities). Opium poppies were grown principally for extraction of alkaloids (from poppy straw) in nine other countries: Australia, China, France, Hungary, Slovakia, Spain, the Republic of Macedonia, Turkey, and the United Kingdom. China ceased producing licit opium after 2001. Opium poppies grown principally for the seed crop, with licit poppy straw as a by-product, were produced in the Czech Republic, Serbia and Montenegro. Another six countries cultivated opium poppies solely for the poppy seed or horticultural purposes, without extraction of alkaloids from poppy straw: Austria, Estonia, Germany, Netherlands, Poland, and Ukraine. Illicit production of Polish heroin and other products derived from poppy straw is an ongoing problem in Poland, although it isn't as serious as in the 1980s, after poppies containing high levels of opioid alkaloids were banned in 1990s. The production of licit opium in India was in accord with terms of the 1961 Single Convention on Narcotic Drugs. After the opium was harvested, the plants were allowed to mature and harvested for poppy seeds. The sale of poppy seeds delivered a significant proportion of the income from the licit opium crop. Unknown fractions of both the opium harvest and the poppy straw residue from the poppy seed harvest were diverted to illicit uses.
For each essential amino acid i, calculate Ti/Ri. Take the amino acid with the smallest value of Ti/Ri. Call it l. This is the limiting amino acid. The AAS is 100% × Tl/Rl. PDCAAS estimates digestibility in a separate procedure. The estimated PD is multiplied with AAS to get PDCAAS.
==== Luca Visentini ==== Visentini was detained on 9 December 2022 and released without charge two days later. In a statement issued through the ITUC, he replied to the allegations by proclaiming his innocence and "reconfirming his absolutely commit[ment] to the fight against corruption" He also commented specifically on his confession in relation to receiving two payments from the NGO Fight Impunity of €50,000 and €60,000 by stating the monies were in relation to his campaign to become the General-Secretary of ITUC and that "it was in no way connected to a corruption attempt or aimed at influencing my position on Qatar." In March 2023 he was dismissed as general-secretary of the ITUC.
Sources: en.wikipedia.org
=== China === In July 2007, officials of the People's Republic of China seized US-produced pork for containing ractopamine residues. Further shipments of Canadian ractopamine-fed pork were seized in September 2007. In June 2019, customs inspectors in China detected ractopamine in a shipment of Canadian pork products destined for Chinese consumption. The Chinese government thereupon suspended not only pork, but also beef imports from Canada. Canadian Agriculture Minister Marie-Claude Bibeau stated that the CRFPCP certificate was a forgery and called in the RCMP, while Canadian Public Safety Minister Ralph Goodale stressed that the federal government would vigorously defend Canadian meat producers. It was also revealed that the Canadian Cattlemen's Association said in a statement that "We are fully confident in our meat production systems in Canada and the safeguards we have in place." Meanwhile, holes were found in the CRFPCP programme because the meat packer at the centre of the controversy was a chilled butcher shop only.<what> It was disclosed on 3 July that the Chinese authorities had discovered 188 falsified CRFPCP certificates.
Ukrainian President Volodymyr Zelenskyy claimed that air defences had shot down some thirty six Shahed drones. In occupied Crimea, the regional governor said six Ukrainian drones were shot down. In an interview with Die Welt, Vadym Skibitsky, deputy head of Ukraine's military intelligence service, said the government intends to assassinate Putin "because he coordinates and decides what happens" in the war. Yevgeny Prigozhin announced the start of the turnover of Bakhmut from his Wagner mercenaries to the Russian military and his forces' withdrawal from the city. He also said they would repatriate the bodies of an American national, whom he identified as a former special forces soldier named Nicholas Maimer, and a Turkish citizen, which they claimed to have recovered from the remains of a building blown up by Ukrainian forces, adding that the body of another Turkish national, a woman, was also found but could not be retrieved. 106 Ukrainian POWs captured in Bakhmut were repatriated to Ukraine in a prisoner exchange with Russia. The FSB announced that it had arrested two members of a Ukrainian "sabotage group" and two Russian accomplices who were plotting to bomb power lines connected to the Leningrad and Kalinin Nuclear Power Plants, adding that 36.5 kilos of explosives and about 60 detonators were recovered from them. The Russian Defence Ministry said it had scrambled Su-27 and Su-35 fighter jets to intercept two US Air Force B-1B strategic bombers near the country's airspace boundary over the Baltic Sea.
==== Chemical ==== Nitrous acid can be used to chemically depolymerize heparin/HS. Nitrous acid can be used at pH 1.5 or a higher pH of 4. Under both conditions, nitrous acid effects deaminative cleavage of the chain. At both 'high' (4) and 'low' (1.5) pH, deaminative cleavage occurs between GlcNS-GlcA and GlcNS-IdoA, albeit at a slower rate at the higher pH. The deamination reaction, and therefore chain cleavage, is regardless of O-sulfation carried by either monosaccharide unit. At low pH, deaminative cleavage results in the release of inorganic SO4, and the conversion of GlcNS into anhydromannose (aMan). Low-pH nitrous acid treatment is an excellent method to distinguish N-sulfated polysaccharides such as heparin and HS from non N-sulfated polysaccharides such as chondroitin sulfate and dermatan sulfate, chondroitin sulfate and dermatan sulfate not being susceptible to nitrous acid cleavage.
The most intense 'peak' is reached within a minute or so and lasts for 1–5 minutes, followed by a gradual tapering off. At 5–10 minutes, less intense yet still noticeable effects typically persist, giving way to a returning sense of the everyday and familiar until back to baseline after about 15 to 20 minutes.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.